Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us

Endorsements

“As a co-founder and editor of a company that reviewed FDA-approved drugs, I found it almost impossible to maintain currency, not only on recently approved agents, but especially those in the pipeline.  To do so, I highly recommend THE PHARMACEUTICAL PIPELINE TRACKER; there are few drug information resources on my "must review" list but this has become one of them.  It not only includes new agents but those in some stage of review which aids both with therapeutic as well as formulary considerations.  Its' salient quality is the concise nature of the information.  It allows a relatively rapid review of a drug's comparative efficacy today as well as what to expect in the future.”
​

 Dennis Cada, PharmD, FASHP, FASCP
Co-founder and Editor, The Formulary  
Consulting Editor, Hospital Pharmacy
 
“I started to use the Pharmaceutical Pipeline Tracker to view what new drugs were on the horizon for mental health. It has been very helpful to me for projecting budgets.  Another benefit I found was tracking the various pharmaceutical companies that had medications at different phases of development in the pipeline and to see the difficult time they had in getting an approval in the process.  It helped to open up my eyes to the length of time and work needed to obtain a new medication, or a new indication approved.
I also used the Pipeline to track which companies may have a break thru medication for my stock club to identify which one was close to gaining approval and may be a good investment.”
 
Fred Tonnies, BS., MS., RPh
Pharmacy Coordinator
Director of Pharmacy (Retired) at the University of Missouri Health System

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.